Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by Padinaon Aug 27, 2020 6:24pm
128 Views
Post# 31467362

Some preclinical timelines

Some preclinical timelinesIt is understandable that people are angry - i also am but truth be told, Goren is right.

Here are some of my other holdings with there preclinical timelines

1) Heat Biologics ticker HTBX began preclinicals in May. Results was announced August ( 2 months +)

2) VBIV working with National reseach Council of Canada began preclinicals in March and result was just released August 26 ( 5 months!)

3) iBio  : Preclinical for its 1st vaccine candidate began in May - we are still awaiting update 
          2nd preclinical for its 2nd vaccine candidate began last week of May report from trial from released August 10 ( 2 months +)

Per timeline given by David, assuming they go with worst case scenario of 6 weeks, the total time for their preclinicals will be aproximately 2.5 months.

I think the timeline is still very much in line with others. I just wished they had began the preclinicals earlier than they did because Science takes time.

GLTA
<< Previous
Bullboard Posts
Next >>